Work

Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage

Year: 2025

Type: article

Abstract: Alemtuzumab-induced diffuse alveolar haemorrhage (DAH) is a rare but serious complication in people with relapsing-remitting multiple sclerosis (RRMS). Evidence supporting retreatment despite adverse events remains limited. We report a 29-year-old female who developed DAH during the first alemtuzumab cycle and was subsequently retreated 1 year later following interdisciplinary advice from respiratory. There was no recurrence of DAH. This case report provides evidence towards retreatment feasibility with regular monitoring and low thresholds for laboratory and radiological investigations.

Source: Multiple Sclerosis Journal

DOI: 10.1177/13524585251365791

Authors: Dylan Haixiang Zhao, Gina Hadley, Marco Pisa, Peter Saunders, Gabriele De Luca

Institutions: University of Oxford, Oxford University Hospitals NHS Trust

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,400